Table II.

Summary of Review Articles on Curcumin Nanoformulations

Details of review article	Description of review article
Bioavailability of curcumin: problems and promises. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Mol Pharm. (2007) 4(6):807–18. (5)	This review article is the first attempt to discuss enhanced bioavailability of curcumin for therapeutic application with human disease.
Advanced drug delivery systems of curcumin for cancer chemoprevention. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Cancer Prev Res. (2011) 4(8):1158–71. (13)	This article describes a broad overview of various delivery systems and discusses future strategies to enable the implementation of such chemopreventive strategies.
Curcumin nanoformulations: a future nanomedicine for cancer. Yallapu MM, Jaggi M, Chauhan SC. Drug Discov Today. (2012) 17(1–2):71–80. (7)	This is the first comprehensive review focused on the design and development of various nanoformulations (nanoparticles, self-assemblies, nanogels, liposomes and complex fabrication) for sustained and efficient curcumin delivery. A few novel multifunctional and composite nanosystem strategies are also discussed due to their simultaneous therapy and imaging characteristics.
Advances in nanotechnology-based delivery systems for curcumin. Sun M, Su X, Ding B, He X, Liu X, Yu A, Lou H, Zhai G. Nanomedicine. (2012) 7(7):1085–100. (14)	This review discusses nanotechnology-based curcumin delivery (liposomes, polymeric nanoparticles, solid lipid nanoparticles, micelles, nanogels, nanosuspensions, nanoemulsions, complexes, and dendrimer/dimer) approaches to enhance oral bioavailability, biological activity, and tissue-targeting ability.
Curcumin nanomedicine: a road to cancer therapeutics. Yallapu MM, Jaggi M, Chauhan SC. Curr Pharm Des. (2013) 19(11):1994–2010. (10)	This study reviews advanced drug delivery of curcumin to leverage therapeutic benefits by improving bioavailability and pharmacokinetics for tumor-specific curcumin.
Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics. Yallapu MM, Ebeling MC, Jaggi M, Chauhan SC. Cur Drug Metab. (2013) 14(4):504–15.(15)	This review examines possible interactions between the surface of curcumin nanoparticles and plasma proteins, the role of nanoparticle–protein complex architecture parameters, and the rational design of clinically useful curcumin nanoformulations.
Nanocurcumin: a promising therapeutic advancement over native curcumin. Flora G, Gupta D, Tiwari A. Crit Rev Ther Drug Carrier Syst. 2013;30(4):331–68. (16)	This review discusses various nanometric formulations of curcumin for its controlled and targeted delivery. It also demonstrates the biological applications, patented technologies, and current status of the ongoing clinical trials related to curcumin nanoformulations.
Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. Biomaterials. (2014) 35(10):3365–83. (12)	This review summarizes the design and development of curcumin nanoformulations utilizing liposomes, polymeric nanoparticles and micelles, conjugates, peptide carriers, cyclodextrins, solid dispersions, lipid nanoparticles, and emulsions. Up-to-date efficacy of curcumin nanoformulations using cancer cell lines, in vivo models, and human clinical trials is also provided.
Nanotechnology-applied curcumin for different diseases therapy. Ghalandarlaki N, Alizadeh AM, Ashkani-Esfahani S, BioMed Res Inter. (2014) Article ID 394264, 23 pages (11)	New additions of nanotechnology approaches for curcumin delivery using liposomes, micelles, niosomes, cyclodextrins, dendrimers, nanogels, chitosans, gold nanoparticles, silver, and solid lipid nanoparticles are reported.
Recent advances in curcumin nanoformulation for cancer therapy. Lee W-H, Loo C-Y, Young PM, Traini D, Mason RS, Rohanizadeh R. Expert Opin. Drug Deliv. (2014) 11(8):1183–1201 (17)	This review reports (1) key properties of nanoparticles: size, surface modification, and targeting; (2) development of liposomal, micelles, nanogels, cyclodextrin–curcumin complexes, and other formulations; and (3) in vitro and in vivo efficacy of curcumin nanoformulations.
Dose escalation and pharmacokinetic study of nanoparticle curcumin. Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, TsujikoK, et al. Cancer Chemother Pharmacol. (2012) 69(1):65–70 (18)	Theracurmin can safely increase plasma curcumin levels in a dose-dependent manner at least up to 210 mg without saturating the absorption system.